Endoscopic Retrograde Cholangiopancreatography Market Research Report— Forecast till 2030

Endoscopic Retrograde Cholangiopancreatography Market Research Report Information by Product (Endoscopes, Endotherapy Devices [Catheters, Stents, Balloons, Guiding Wires , and Others], Imaging Systems, and Energy Devices), By Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Duct Stenting, and Others), By Application (Bile Duct, Pancreas, and Others) and By End User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others) and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - For

ID: MRFR/HC/9611-HCR | February 2023 | Region: Global | 120 Pages         

Endoscopic Retrograde Cholangiopancreatography Market

Endoscopic Retrograde Cholangiopancreatography Market is expected to grow USD 2,892.49 Million at a CAGR 9.8% during the forecast period 2022-2030.

Segmentation
By Product Endoscopes Endotherapy Devices Energy Devices
By Procedure Biliary Sphincterotomy Biliary Stenting Biliary Dilatation Pancreatic Duct Stenting and Others
By Application Bile Duct Pancreas and Others
By End User Hospitals & Clinics Ambulatory Surgical Centers Others
Key Players
Companies Profiled    Olympus Corporation (Japan)    Fujifilm Holdings    Corporation (Japan)    STERIS PLC (UK)    Cook Medical (US)    Boston Scientific Corporation (US)    CONMED Corporation (US)    HOYA Group (Japan)    Q3 Medical Devices Limited (Ireland)    Ambu Inc (Denmark)    Medtronic Plc (Ireland)    Others
Drivers
Market Driving Forces   Increasing prevalence of gastrointestinal diseases (GIT) associated with the pancreas and bile ducts    Rising demand for minimally invasive surgeries
Request a Free Sample

Global Endoscopic Retrograde Cholangiopancreatography Market Forecast


The endoscopic retrograde cholangiopancreatography market size is expected to reach USD 2,892.49 million by 2030 at 9.8% CAGR during the forecast period (2022 - 2030).


Endoscopic Retrograde Cholangiopancreatography (ERCP) is a type of procedure that includes combination of upper gastrointestinal endoscopy and fluoroscopy. This procedure diagnoses and treats diseases related to the bile duct, pancreas, gall bladder, and liver. The ERCP can diagnose blockages or stones in the bile ducts, fluid leakage from the bile or pancreatic ducts, blockages or narrowing of the pancreatic ducts, tumors, and infection in the bile ducts. The factors affecting the ERCP market are the increasing prevalence of gastrointestinal diseases (GIT) associated with the pancreas & bile ducts and the rising demand for minimally invasive surgeries. Moreover, the market growth opportunities projected during the forecast period are driven by technological advancements. However, the side effects associated with post-ERCP, and lack of skilled physicians are hindering the market growth.


COVID-19 Analysis


The COVID-19 has had negative impact on the ERCP supply chain and has reduced the number of elective ERCP procedures. ly, people were requested to follow government rules, such as travel restriction and social distancing which reduced medical access for such procedures. The hospitals, ambulatory surgical centers, and diagnostic centers stopped and delayed the ERCP treatment and diagnosis which negatively impacted the market growth. Moreover, raw materials needed to manufacture ERCP devices (steel, titanium, nitinol, and an alloy of nickel) were in short supply during the first and second waves of COVID-19. This is owing to the prolonged lockdowns in major economies such as India and Italy, the export of ERCP devices across international borders had been affected. Moreover, most of the world’s leading endoscopy device companies have manufacturing facilities in China. As China was the epicenter of this outbreak, it had suspended most industrial activities. Therefore, the timely delivery of these devices had been affected, and market trends related to ERCP endoscopy have been negatively affected.


Furthermore, there were also concerns regarding the transmission of COVID-19 among patients undergoing ERCP procedures. This is owing to the potential generation of SARS-CoV-2-contaminated aerosols from the CO2 leakage and the creation of smoke from the use of energy devices. Many experts have also suggested that to prevent and manage aerosol dispersion, the insufflation process of endoscopic procedures should also be conducted very carefully. Additionally, electrosurgical, and ultrasonic devices were also advised to be employed in a manner that minimizes surgical smoke production with low power settings, and prolonged activation of these devices should also be avoided.


Endoscopic Retrograde Cholangiopancreatography Market Dynamics


Market Drivers



  • Increasing prevalence of gastrointestinal diseases (GIT) associated with the pancreas and bile ducts


There are several diseases that affect the pancreas and bile ducts. The diseases include alcohol-related pancreatitis, gallstone pancreatitis, diabetes, gallstones bile duct stones, and chronic pancreatitis. The major factors in having these diseases are infection, injury or trauma to the abdomen, and alcoholism. In 2022, according to the American Cancer Society, it is estimated that 62,210 people will be diagnosed with pancreatic cancer. Furthermore, it was stated that the US accounts for 7% of pancreatic cancer deaths ly. Hence, the increasing gastrointestinal diseases further lead to pancreas and bile duct diseases, which fuel the growth of the market.



  • Rising demand for minimally invasive surgeries


Market Restraints




  • Side effects associated with post-ERCP

    • The ERCP side effects pose a threat to market growth owing to the risk to patients. There are some common and temporary side effects, including a temporary sore throat, temporary tiredness, difficulty concentrating, and bloating. Moreover, its severe side effects include organ perforation, infection, oversedation, and pancreatitis. Furthermore, according to the study, 8-10% of ERCP procedure have complications. As a result of the temporary and permanent side effects post-ERCP, this hinders the growth of the market.



  • Lack of skilled physicians


Market Opportunities




  • Technological advancements

    • The technological advancements achieved through strategic alliances further create lucrative growth opportunities for the market. Medical technology companies are developing products to improve the success rate of ERCP. Further, the market players are focusing on developing devices for complex ERCP procedures. For example, in January 2020, Olympus Corporation (Japan) received US Food and Drug Administration approval for the TJF-Q190V duodenoscope, which includes a sterile and disposable distal endcap. Furthermore, it addresses the physician's needs by providing lifesaving ERCP to critically ill patients. As a result, technological advancements to meet physician demand through medical technology providers create additional opportunities during the forecast period.




Value Chain Analysis


The endoscopic retrograde cholangiopancreatography market is projected to exhibit significant growth over the forecast period, which can be attributed to factors like the increasing minimally invasive surgery and rising prevalence of GIT diseases. The value chain analysis for the market comprises five major components, which start with research and product development, followed by the manufacturing of the products, distribution, and sales, and end with post-marketing surveillance.


Endoscopic Retrograde Cholangiopancreatography Market Segmentation


Product Insights



  • Endoscopes


An endoscope is a medical device that combines fluoroscopy and endoscopy. The endoscope device is used to examine blockages of the bile and pancreatic ducts, irregularities in the tissue, problems with the flow of bile or pancreatic fluid, tumors, or stones.



  • Endotherapy Devices


Endotherapy devices include catheters, guiding wires, stents, balloons, and others. The catheter enables the biliary and pancreatic derivatives to be examined. Guidewires are used to add value to advanced devices as well as to maintain and gain access to desired ducts. Stents are used to bypass strictures in the pancreatic and bile ducts. Moreover, a balloon fitted with a catheter is used to stretch the narrow areas, mostly in benign tumors. Further, the other types of endotherapy devices include cannulas, forceps, and snares.



  • Imaging Systems


These systems provide Magnetic Resonance Cholangiopancreatography (MRCP) and Computed Tomography (CT), which are non-invasive techniques. As per the research, the MRCP has been proven to provide more appropriate results than the CT. The MRCP assists in diagnosing bile duct cancer, bile duct stones, dilated bile ducts, pancreatic cysts, pseudocysts, etc. There are two types of Magnetic Resonance Imaging (MRI) scanners used: closed-bore MRI and open-bore MRI.



  • Energy Devices


The energy devices include electrosurgical generators, a smoke evacuation system, and electrosurgical accessories. There are electrosurgical generators that have both monopolar and bipolar options as well as offering pure cutting, pure coagulation, and blended (cut/coagulation) current modes. Moreover, as per the research, monopolar instruments are used for specific procedures, including sphincterotomes for ERCP.


Procedure Insights



  • Biliary Sphincterotomy


A biliary sphincterotomy procedure cuts the muscle between the common bile duct and the pancreatic duct. It is done to remove stones and for the treatment of bile leaks. Further, the procedure uses a catheter and wire to remove gallstones or blockages. This removes the stones and deposits them in the intestine, allowing them to pass through more quickly.



  • Biliary Stenting


Biliary stenting is a minimally invasive surgical procedure done through the insertion of a stent tube. These stents can be made of a single plastic stent or a Self-expanding Metal Stent (SEMS), which are used to treat biliary leaks and obstructions in the biliary tree.



  • Biliary Dilatation


This procedure is used to dilate narrow bile ducts. Conditions that can cause the narrowing of sphincters include chronic pancreatitis, primary sclerosing cholangitis, and papillary stenosis. Moreover, it has been found that in developing countries, people suffer more from narrow strictures owing to the parasites that invade the biliary tree.



  • Pancreatic Duct Stenting


The pancreatic duct stent procedure utilizes small-diameter tubes that have a pigtail and are "J" shaped. The stents are typically made of polyethene or materials that are similar to biliary stents, such as plastic and metal stents. It is used to bypass obstructing pancreatic duct stones and the pancreas divisum, bridge dominant strictures, drain pseudocysts, seal duct disruptions, and prevent procedure-induced pancreatitis.



  • Others


Other procedure includes pancreatic duct dilatation and pancreatic sphincterotomy. The pancreatic duct dilatation procedure performed to treat the pancreatic cancer. Furthermore, it is also used in diseased pancreas and chronic pancreatitis.


Application Insights



  • Bile Duct


Endoscopic retrograde cholangiopancreatography is used to diagnose and treat conditions related to the bile duct, stones, and structures. The blockage in the bile duct is caused by gallstones or sludge. Furthermore, gallbladder stone prevalence is influenced by changes in lifestyle and mostly appears in developing regions.



  • Pancreas


Endoscopic retrograde cholangiopancreatography is a procedure used to diagnose and treat several conditions related to the pancreas. The conditions include pancreatic duct obstruction, which includes sphincter dysfunction or anomalies. As per the research, the diagnosis and palliation of pancreatic cancer can be achieved through ERCP when done appropriately. Moreover, as per the World Cancer Research Fund International, pancreatic cancer is the twelve most common cancer in men and the eleven most common in women. In addition, there were 495,000 new pancreatic cancer cases across the globe in 2020. Hence, increasing prevalence of pancreatic cancer further fueling segment growth.



  • Others


Other applications include the gallbladder and liver related diagnosis and treatments. ERCP is used to treat and diagnose gallstones and cholecystitis (inflammation of the gallbladder).


End User Insights



  • Hospitals & Clinics


The extensive number of ERCPs performed in the hospitals & clinics. This is due to the increasing prevalence of diseases associated with the gall bladder, pancreas, liver, and bile duct. Hospitals are rapidly adopting innovative technologies and procedures to provide effective services. Hospitals & clinics are focusing more on technology upgradation, leading to improved efficiency of treatment. In the last few years, the number of patients suffering from GIT diseases has increased significantly. Since advanced treatment procedures are available in hospitals as well as clinics, and the increasing prevalence of GIT diseases is further fueling the segment's growth.



  • Ambulatory Surgical Centers


The growing healthcare expenditure worldwide and the adoption of advanced technology make ERCP feasible at Ambulatory Surgical Centers (ASCs). The higher-risk population prefers ERCP under the supervision of anesthesia in ASCs. As ERCP has been proved to be safe to perform in the ASCs as all the special equipment available at ASCs. Moreover, ASCs have trained physicians to provide appropriate procedures based on this knowledge.



  • Others


Other end users include diagnostic centers and research & academic centers. The substantial number of MRCPs performed to diagnose diseases at diagnostic centers. Diagnostic centers are an appropriate place to diagnose diseases associated with the pancreas, bile, liver, and gallstones with the availability of proper equipment. Due to the complexity associated with MRCP process; a large number of patients prefer diagnostic centers for diagnosis. Moreover, the diagnostic centers perform MRCP to evaluate various conditions of the pancreaticobiliary duct system. The conditions include the identification of congenital anomalies of the cystic and hepatic ducts, post-surgical biliary anatomy and complications, pancreas divisum, anomalous pancreaticobiliary junction, choledocholithiasis, biliary strictures, chronic pancreatitis, pancreatic cystic lesions, and trauma to the biliary system. Moreover, research and academic centres use the information available associated with the ERCP procedure, complications, and advantages in order to research and develop the appropriate treatments.


Regional Analysis


The endoscopic retrograde cholangiopancreatography market based on the region has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World.


North America


The increasing prevalence of liver and bile intrahepatic cancer and strategic alliances are projected to propel the region’s market growth.


The North America region is expected to grow the most during the forecast period. This is due to several factors, including the rising prevalence of liver and bile intrahepatic cancer and growth strategies among regional market players. As per the American Cancer Society, approximately 41,260 new cases of primary liver cancer and intrahepatic bile duct cancer patients are estimated to be diagnosed in 2022. Furthermore, approximately 30,520 people are expected to die in 2022 as a result of primary liver cancer and the intrahepatic bile duct. Moreover, companies launch new products in order to broaden their product portfolio and cater to customer requirements worldwide. For instance, in December 2019, Boston Scientific Corporation (US) launched the EXALT Model D single use (disposable) duodenoscope for ERCP procedures. Therefore, the increasing prevalence of cancer and product launches are supporting market growth in the region.


Competitive Landscape


Market players are improving business through planning and adopting new strategies to increase their market presence. Moreover, they are adopting several strategic initiatives with regard to endoscopic retrograde cholangiopancreatography, such as new product launches, contractual agreements, mergers, and acquisitions, increasing investments, and partnerships among players are aiding to expand the endoscopic retrograde cholangiopancreatography field across the globe.


Olympus Corporation (Japan) is one of the key players, founded in 1919. It is a microscope manufacturing company. It has succeeded in developing the world’s first practical gastrocamera. It develops, manufactures, and sells medical, healthcare, imaging, information, and other industrial equipment and devices. In October 2020, Olympus launched the StoneMasterV and VorticCatchV endotherapy devices in order to increase the efficiency of bile duct stone management and retrieval for ERCP.


List of companies covered in this report:



  • Olympus Corporation (Japan)

  • Fujifilm Holdings Corporation (Japan)

  • STERIS PLC (UK)

  • Cook Medical (US)

  • Boston Scientific Corporation (US)

  • CONMED Corporation (US)

  • HOYA Group (Japan)

  • Q3 Medical Devices Limited (Ireland)

  • Ambu Inc. (Denmark)

  • Medtronic Plc (Ireland)

  • Others


Recent Developments



  • In July 2020, Ambu Inc. (Denmark) received US Food and Drug Administration (FDA) approval for an Ambu aScope Duodeno, which is a sterile, single use duodenoscope.

  • In January 2020, PENTAX Medical, a subsidiary of HOYA Group, launched the DEC HD Duodenoscope in the US. It is an advanced, high deficiency duedenoscope that includes the sterile distal cap and elevator lever for unit reprocessing.

  • In June 2019, Olympus Corporation launched HANAROSTENT self-expanding metal stents (SEMS) for the endotherapy procedure that includes duodenal uncovered stents.

  • In September 2021, QualiMed Innovative Medizinprodukte GmbH (Germany), a subsidiary of Q3 Medical Devices Limited (Ireland), launched the Balloon Expandable Biodegradable Biliary Stent (BEBS). This is a biodegradable metal alloy-based stent implant for biliary applications.


Report Overview


The study covers the existing short-term and long-term market effects. It helps decision-makers to draw up short-term and long-term business plans by region. The report covers major regions in North America, Europe, Asia-Pacific, and the rest of the world. The report analyses market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and impact of COVID-19 on the market.


Study Objectives



  • To provide a detailed analysis of the market structure and forecast for the various segments of the endoscopic retrograde cholangiopancreatography market over the next eight years.

  • To provide insights about factors affecting the market's growth.

  • To analyzes the endoscopic retrograde cholangiopancreatography market based on numerous factors such as price analysis, supply chain analysis, Porter's five force analysis, etc.

  • To provide historical and forecast revenues of the market segments and sub-segments concerning four main geographies and their countries: North America, Europe, Asia-Pacific, and the Rest of the World.

  • To provide a country-level market analysis for the current market size and prospects.

  • To provide a country-level analysis of the market for segments by product, procedure, application, and end-user.

  • To provide strategic profiling of key players in the market, comprehensively analyze their core competencies, and draw a competitive market landscape.

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers & acquisitions, new product developments, and R&D in the Endoscopic retrograde cholangiopancreatography market.


Endoscopic Retrograde Cholangiopancreatography Market Segmentation:


Product Outlook



  • Endoscopes

    • Endotherapy Devices

    • Catheters

    • Stents

    • Balloons

    • Guiding Wires

    • Others



  • Imaging Devices

  • Energy Devices


Procedure Outlook



  • Biliary Sphincterotomy

  • Biliary Stenting

  • Biliary Dilatation

  • Pancreatic Duct Stenting

  • Others


Application Outlook



  • Bile Duct

  • Pancreas

  • Others


End User Outlook



  • Hospitals & Clinics

  • Ambulatory Surgical Centers

  • Others


Region Outlook


North America


  • US

  • Canada


Europe


  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Rest of Europe


Asia-Pacific


  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Rest of Asia-Pacific

  • Rest of the World

  • Middle East

  • Africa

  • Latin America


Intended Audience:



  • Endoscopic Retrograde Cholangiopancreatography Product Manufacturers and Suppliers

  • Research and Development (R&D) Companies

  • Healthcare Providers

  • Government & Independent Research Laboratories

  • Government and Independent Regulatory Authorities

  • Market Research and Consulting Service Providers

  • Academic Institutes and Universities



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 2,892.49 million
  CAGR   9.8%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product, Procedure, Application, and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World
  Key Vendors   Olympus Corporation (Japan), Fujifilm Holdings, Corporation (Japan), STERIS PLC (UK), Cook Medical (US), Boston Scientific Corporation (US), CONMED Corporation (US), HOYA Group (Japan), Q3 Medical Devices Limited (Ireland), Ambu Inc. (Denmark), Medtronic Plc (Ireland), Others
  Key Market Opportunities   Technological advancements
  Key Market Drivers   â€˘ Increasing prevalence of gastrointestinal diseases (GIT) associated with the pancreas and bile ducts • Rising demand for minimally invasive surgeries


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The endoscopic retrograde cholangiopancreatography market size is expected to reach USD 2,892.49 million by 2030 at 9.8% CAGR during the forecast period (2022 - 2030).

Olympus Corporation (Japan), Fujifilm Holdings, Corporation (Japan), STERIS PLC (UK), Cook Medical (US), Boston Scientific Corporation (US), CONMED Corporation (US), HOYA Group (Japan), Q3 Medical Devices Limited (Ireland), Ambu Inc. (Denmark), Medtronic Plc (Ireland) are the key players in the market

North America holds the largest share in the global market of Endoscopic Retrograde Cholangiopancreatography.

Increasing prevalence of gastrointestinal diseases (GIT) associated with the pancreas and bile ducts and Rising demand for minimally invasive surgeries

Side effects associated with post-ERCP and Lack of skilled physicians